Scholars@Duke

Men with advanced breast cancer (BC): Initial phase (Ph) 2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor

Publication ,  Conference
Elias, A; Gucalp, A; Bardia, A; Resaul, A; Eisner, J; Baskin-Bey, E; Traina, TA
Published in: CANCER RESEARCH
2018

Duke Scholars

Joel Robert Eisner
Author Joel Robert Eisner Pharmacology & Cancer Biology

Published In

CANCER RESEARCH

EISSN

1538-7445

ISSN

0008-5472

Publication Date

2018

Volume

78

Issue

4

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Elias, A., Gucalp, A., Bardia, A., Resaul, A., Eisner, J., Baskin-Bey, E., & Traina, T. A. (2018). Men with advanced breast cancer (BC): Initial phase (Ph) 2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor. In CANCER RESEARCH (Vol. 78).
Elias, Anthony, Ayca Gucalp, Aditya Bardia, Andrew Resaul, Joel Eisner, Edwina Baskin-Bey, and Tiffany A. Traina. “Men with advanced breast cancer (BC): Initial phase (Ph) 2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor.” In CANCER RESEARCH, Vol. 78, 2018.

Published In

CANCER RESEARCH

EISSN

1538-7445

ISSN

0008-5472

Publication Date

2018

Volume

78

Issue

4

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis